Clinical Trial Detail

NCT ID NCT02318901
Title Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Western Regional Medical Center
Indications

Her2-receptor positive breast cancer

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

stomach cancer

colorectal cancer

Therapies

Pembrolizumab + trastuzumab emtansine

Pembrolizumab + Trastuzumab

Pembrolizumab + Cetuximab

Age Groups: adult

Additional content available in CKB BOOST